{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:54:16Z","timestamp":1793717656177,"version":"4.6.1"},"reference-count":53,"publisher":"American Society of Hematology","issue":"19","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a clonal plasma cell malignancy that is characterized by genetic heterogeneity. The cytogenetic abnormality t(4;14) strongly predicts poor outcome in patients with MM, even in the era of novel drugs. Ferroptosis is a new approach to antitumor therapy, but the relationship between ferroptosis and MM cytogenetic abnormalities remains largely unclear. In this study, we show that t(4;14)-positive but not t(4;14)-negative MM cells are susceptible to class II ferroptosis inducers (FINs) in a preclinical setting, which is dependent on the significant upregulation of the MM SET domain-containing protein (MMSET). Mechanistically, MMSET upregulates acyl-coenzyme A synthetase long-chain family member 4 transcription by binding to its promoter region, leading to increased polyunsaturated fatty acid (PUFA) levels and enhanced sensitivity of t(4;14)-positive MM cells to ferroptosis. Supplementation with PUFAs efficiently restores the susceptibility of t(4;14)-negative MM cells to ferroptosis. In addition, combining class II FIN treatment with bortezomib in t(4;14)-positive MM cells attenuates cellular glutathione and induces both apoptosis and ferroptosis levels by inhibiting the increase in solute carrier family 7 member 11, demonstrating synergistic antitumor activity in\u00a0vitro and in a xenograft model. Taken together, our findings suggest that targeting ferroptosis with class II FINs is a novel and promising therapeutic approach to improve the outcome of t(4;14)-positive patients with MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010335","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T17:03:20Z","timestamp":1721754200000},"page":"5022-5038","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma"],"prefix":"10.1182","volume":"8","author":[{"given":"Jiasi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8727-5258","authenticated-orcid":false,"given":"Fengjuan","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoshuang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-4568","authenticated-orcid":false,"given":"Yu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"issue":"9983","key":"2024100812452787200_bib1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Rollig","year":"2015","journal-title":"Lancet"},{"issue":"10272","key":"2024100812452787200_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2024100812452787200_bib3","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"2024100812452787200_bib4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2024100812452787200_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12185-020-03005-6","article-title":"Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents","volume":"113","author":"Sato","year":"2021","journal-title":"Int J Hematol"},{"issue":"9","key":"2024100812452787200_bib6","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","article-title":"The t(4;14) Translocation in myeloma dysregulates both FGFR3and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts","volume":"92","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"2024100812452787200_bib7","doi-asserted-by":"crossref","first-page":"636514","DOI":"10.1155\/2014\/636514","article-title":"MMSET: role and therapeutic opportunities in multiple myeloma","volume":"2014","author":"Xie","year":"2014","journal-title":"BioMed Res Int"},{"issue":"20","key":"2024100812452787200_bib8","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/0008-5472.CAN-13-1000","article-title":"NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"2024100812452787200_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","article-title":"The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells","volume":"117","author":"Martinez-Garcia","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2024100812452787200_bib10","doi-asserted-by":"crossref","first-page":"e1004566","DOI":"10.1371\/journal.pgen.1004566","article-title":"Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation","volume":"10","author":"Popovic","year":"2014","journal-title":"PLoS Genet"},{"issue":"10","key":"2024100812452787200_bib11","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2004-09-3704","article-title":"Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients","volume":"105","author":"Keats","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2024100812452787200_bib12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2012.269","article-title":"MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC","volume":"27","author":"Min","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"2024100812452787200_bib13","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/leu.2015.169","article-title":"MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib","volume":"29","author":"Xie","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"2024100812452787200_bib14","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1021\/acs.jmedchem.2c01920","article-title":"Structural modification and pharmacological evaluation of substituted quinoline-5,8-diones as potent NSD2 inhibitors","volume":"66","author":"Tang","year":"2023","journal-title":"J\u00a0Med Chem"},{"issue":"16","key":"2024100812452787200_bib15","doi-asserted-by":"crossref","first-page":"10991","DOI":"10.1021\/acs.jmedchem.3c00948","article-title":"Drug discovery targeting nuclear receptor binding SET domain protein 2 (NSD2)","volume":"66","author":"Ma","year":"2023","journal-title":"J\u00a0Med Chem"},{"issue":"5","key":"2024100812452787200_bib16","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"51","key":"2024100812452787200_bib17","doi-asserted-by":"crossref","first-page":"e1904197","DOI":"10.1002\/adma.201904197","article-title":"Recent progress in ferroptosis inducers for cancer therapy","volume":"31","author":"Liang","year":"2019","journal-title":"Adv Mater"},{"key":"2024100812452787200_bib18","doi-asserted-by":"crossref","first-page":"14844","DOI":"10.1038\/ncomms14844","article-title":"Inhibiting the system xC(-)\/glutathione axis selectively targets cancers with mutant-p53 accumulation","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"issue":"1-2","key":"2024100812452787200_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"issue":"5","key":"2024100812452787200_bib20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening horizons: the role of ferroptosis in cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2024100812452787200_bib21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4143\/crt.2016.572","article-title":"Ferroptosis: a novel anti-tumor action for cisplatin","volume":"50","author":"Guo","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"7679","key":"2024100812452787200_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"issue":"6","key":"2024100812452787200_bib23","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","article-title":"Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer","volume":"81","author":"Ghoochani","year":"2021","journal-title":"Cancer Res"},{"issue":"4","key":"2024100812452787200_bib24","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/jcp.29232","article-title":"Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin","volume":"235","author":"Zhang","year":"2020","journal-title":"J\u00a0Cell Physiol"},{"issue":"10","key":"2024100812452787200_bib25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.chembiol.2022.06.004","article-title":"Context-dependent regulation of ferroptosis sensitivity","volume":"29","author":"Magtanong","year":"2022","journal-title":"Cell Chem Biol"},{"issue":"1","key":"2024100812452787200_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nchembio.2239","article-title":"ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition","volume":"13","author":"Doll","year":"2017","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2024100812452787200_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41556-021-00818-3","article-title":"PKCbetaII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis","volume":"24","author":"Zhang","year":"2022","journal-title":"Nat Cell Biol"},{"issue":"3","key":"2024100812452787200_bib28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/carcin\/bgad015","article-title":"ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis","volume":"44","author":"Zhang","year":"2023","journal-title":"Carcinogenesis"},{"issue":"3","key":"2024100812452787200_bib29","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1073\/pnas.1908158117","article-title":"High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model","volume":"117","author":"Luchtel","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2024100812452787200_bib30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3324\/haematol.2020.259531","article-title":"APR-246 induces early cell death by ferroptosis in acute myeloid leukemia","volume":"107","author":"Birsen","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"2024100812452787200_bib31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2015.158","article-title":"Ferroptosis: process and function","volume":"23","author":"Xie","year":"2016","journal-title":"Cell Death Differ"},{"issue":"30","key":"2024100812452787200_bib32","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024100812452787200_bib33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J"},{"issue":"W1","key":"2024100812452787200_bib34","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"2024100812452787200_bib35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/carcin\/bgac080","article-title":"Integrative analysis of enrichment and prognostic value of ferroptosis-related genes and pathways in multiple myeloma","volume":"43","author":"Su","year":"2022","journal-title":"Carcinogenesis"},{"issue":"9","key":"2024100812452787200_bib36","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00432-018-2699-0","article-title":"Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines","volume":"144","author":"Codenotti","year":"2018","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"7","key":"2024100812452787200_bib37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","article-title":"Targeting ferroptosis as a vulnerability in cancer","volume":"22","author":"Lei","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"2024100812452787200_bib38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.phrs.2016.01.029","article-title":"Oxidative stress and proteasome inhibitors in multiple myeloma","volume":"105","author":"Lipchick","year":"2016","journal-title":"Pharmacol Res"},{"key":"2024100812452787200_bib39","doi-asserted-by":"crossref","first-page":"949863","DOI":"10.3389\/fphar.2022.949863","article-title":"ACSL4 as a potential target and biomarker for anticancer: from molecular mechanisms to clinical therapeutics","volume":"13","author":"Hou","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024100812452787200_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2020.12.019","article-title":"ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc\/SREBP1 pathway","volume":"502","author":"Chen","year":"2021","journal-title":"Cancer Lett"},{"issue":"6","key":"2024100812452787200_bib41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni","year":"2022","journal-title":"Blood"},{"issue":"51","key":"2024100812452787200_bib42","doi-asserted-by":"crossref","first-page":"32433","DOI":"10.1073\/pnas.2006828117","article-title":"Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer","volume":"117","author":"Lee","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2024100812452787200_bib43","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3390\/cells10092287","article-title":"Omega-3 fatty acids DHA and EPA reduce bortezomib resistance in multiple myeloma cells by promoting glutathione degradation","volume":"10","author":"Chen","year":"2021","journal-title":"Cells"},{"issue":"23","key":"2024100812452787200_bib44","doi-asserted-by":"crossref","first-page":"12731","DOI":"10.3390\/ijms222312731","article-title":"Phosphocatalytic kinome activity profiling of apoptotic and ferroptotic agents in multiple myeloma cells","volume":"22","author":"Logie","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2024100812452787200_bib45","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1038\/bcj.2016.56","article-title":"Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells","volume":"6","author":"Starheim","year":"2016","journal-title":"Blood Cancer J"},{"key":"2024100812452787200_bib46","doi-asserted-by":"crossref","first-page":"999688","DOI":"10.3389\/fonc.2023.999688","article-title":"A\u00a0novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma","volume":"13","author":"Gao","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"2024100812452787200_bib47","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2024100812452787200_bib48","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12935-022-02742-4","article-title":"Integrated assessment of the clinical and biological value of ferroptosis-related genes in multiple myeloma","volume":"22","author":"Fu","year":"2022","journal-title":"Cancer Cell Int"},{"key":"2024100812452787200_bib49","doi-asserted-by":"crossref","first-page":"215649","DOI":"10.1016\/j.canlet.2022.215649","article-title":"System Xc(-) inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance","volume":"535","author":"Wang","year":"2022","journal-title":"Cancer Lett"},{"issue":"16","key":"2024100812452787200_bib50","doi-asserted-by":"crossref","first-page":"15328","DOI":"10.1021\/acsnano.3c04632","article-title":"Ferroptosis nanomedicine: clinical challenges and opportunities for modulating tumor metabolic and immunological landscape","volume":"17","author":"Yang","year":"2023","journal-title":"ACS Nano"},{"key":"2024100812452787200_bib51","doi-asserted-by":"crossref","first-page":"118077","DOI":"10.1016\/j.lfs.2020.118077","article-title":"FTY720 induces ferroptosis and autophagy via PP2A\/AMPK pathway in multiple myeloma cells","volume":"260","author":"Zhong","year":"2020","journal-title":"Life Sci"},{"issue":"1","key":"2024100812452787200_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-020-04170-5","article-title":"Artemisinin-type drugs for the treatment of hematological malignancies","volume":"87","author":"Mancuso","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2024100812452787200_bib53","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41375-020-0962-2","article-title":"The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma","volume":"35","author":"Longo","year":"2021","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5022\/2245618\/blooda_adv-2023-010335-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5022\/2245618\/blooda_adv-2023-010335-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:17:18Z","timestamp":1728389838000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/19\/5022\/517131\/Class-II-ferroptosis-inducers-are-a-novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":53,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010335","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]}}}